Editorials
Missing clinical trial data
BMJ 2012; 344 doi: https://doi.org/10.1136/bmj.d8158 (Published 03 January 2012) Cite this as: BMJ 2012;344:d8158Related articles
- Research Published: 03 January 2012; BMJ 344 doi:10.1136/bmj.d7202
- Research Published: 03 January 2012; BMJ 344 doi:10.1136/bmj.d7292
- Research Published: 03 January 2012; BMJ 344 doi:10.1136/bmj.d7373
- Research Published: 03 January 2012; BMJ 344 doi:10.1136/bmj.d8141
- Research Published: 03 January 2012; BMJ 344 doi:10.1136/bmj.d7501
- Research Published: 03 January 2012; BMJ 344 doi:10.1136/bmj.d7762
- Analysis Published: 11 January 2011; BMJ 342 doi:10.1136/bmj.c7258
- Editor's Choice Published: 05 January 2012; BMJ 344 doi:10.1136/bmj.e14
- Research Methods & Reporting Published: 03 January 2012; BMJ 344 doi:10.1136/bmj.d8013
- Editorial Published: 26 June 2012; BMJ 344 doi:10.1136/bmj.e4383
- News Published: 02 October 2012; BMJ 345 doi:10.1136/bmj.e6629
- News Published: 23 October 2012; BMJ 345 doi:10.1136/bmj.e7168
- Feature Published: 12 July 2013; BMJ 347 doi:10.1136/bmj.f4465
- Research Published: 28 April 2014; BMJ 348 doi:10.1136/bmj.g2688
- Editorial Published: 05 February 2015; BMJ 350 doi:10.1136/bmj.h599
- Research Methods & Reporting Published: 14 May 2015; BMJ 350 doi:10.1136/bmj.h1793
- Research Published: 12 April 2016; BMJ 353 doi:10.1136/bmj.i1246
- Analysis Published: 25 May 2016; BMJ 353 doi:10.1136/bmj.i2574
- Student Published: 11 June 2014; BMJ 348 doi:10.1136/sbmj.g3288
See more
- Cancer drugs remain FDA approved despite lack of benefit, study findsBMJ December 06, 2016, 355 i6568; DOI: https://doi.org/10.1136/bmj.i6568
- Johnson & Johnson is ordered to pay $1bn over faulty hip implantsBMJ December 06, 2016, 355 i6551; DOI: https://doi.org/10.1136/bmj.i6551
- Bill to boost medical research funding and speed drug approval passes US houseBMJ December 01, 2016, 355 i6498; DOI: https://doi.org/10.1136/bmj.i6498
- Trial of novel leukaemia drug is stopped for second time after two more deathsBMJ November 25, 2016, 355 i6376; DOI: https://doi.org/10.1136/bmj.i6376
- Promise of new Alzheimer’s drug is dashed after lack of evidenceBMJ November 24, 2016, 355 i6362; DOI: https://doi.org/10.1136/bmj.i6362
Cited by...
- Target and actual sample sizes for studies from two trial registries from 1999 to 2020: an observational study
- Subgroup analyses of the effectiveness of oral glucosamine for knee and hip osteoarthritis: a systematic review and individual patient data meta-analysis from the OA trial bank
- Screening for prostate cancer: time to put all the data on the table
- Re-evaluation of the traditional diet-heart hypothesis: analysis of recovered data from Minnesota Coronary Experiment (1968-73)
- Trends in global clinical trial registration: an analysis of numbers of registered clinical trials in different parts of the world from 2004 to 2013
- CONSORT extension for reporting N-of-1 trials (CENT) 2015: Explanation and elaboration
- Why data sharing should be the expected norm
- Discontinuation and non-publication of surgical randomised controlled trials: observational study
- Impact of sending email reminders of the legal requirement for posting results on ClinicalTrials.gov: cohort embedded pragmatic randomized controlled trial
- Discrepancies in autologous bone marrow stem cell trials and enhancement of ejection fraction (DAMASCENE): weighted regression and meta-analysis
- Discrepancies in autologous bone marrow stem cell trials and enhancement of ejection fraction (DAMASCENE): weighted regression and meta-analysis
- How should clinical trial data be shared?
- The Limits of Evidence-Based Medicine and Its Application to Mental Health Evidence-Based Practice: Part One
- FDA given new powers over data reporting to national clinical trials registry
- Open science and reproducible research
- A cost-utility analysis of transcatheter aortic valve implantation in Belgium: focusing on a well-defined and identifiable population
- Are Published Papers Trustworthy?
- Open Science and Data Sharing in Clinical Research: Basing Informed Decisions on the Totality of the Evidence